A trial update on survodutide was recorded on August 21, 2026. The study, registered as NCT06632444 and titled "LIVERAGE: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis," is listed as a Phase 3 trial.
According to the registry entry, the trial's current status is recruiting. The study is designed to evaluate survodutide in people with NASH/MASH who have moderate or advanced liver fibrosis, as stated in the trial title.
No results have been posted for this trial as of this update. The status reflects only that participant recruitment is underway, not any outcome or efficacy finding. Survodutide remains an unapproved compound under research and is not approved for treatment of NASH/MASH or any liver condition.
Readers should treat this as a status update only. Details on trial design, eligibility, and endpoints are available through the official registry listing. For more background on survodutide, including its research status and other studies, see the compound overview.